Hypha Labs AI Stock Analysis
Want to see FUNI full AI Analyst Report?
Hypha Labs (FUNI) AI Stock Analysis
Hypha Labs
(Other OTC:FUNI)
FUNI's overall score of 42 is driven primarily by weak financial performance, with no revenue, persistent losses, and negative equity posing significant risks. Technical indicators show mixed trends with bearish short-term momentum, and the negative P/E ratio further weighs on the score.
Hypha Labs (FUNI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $327.79K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.15
- Revenue Growth
- ―
- EPS Growth
- 47.23%
- Country
- US
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Hypha Labs Business Overview & Revenue Model
Company Description
Hypha Labs, Inc. focuses on the investigation, development, and market release of bioreactor systems across the United States. Their key offering is the Hypha Micropearl bioreactor, a specialized household device engineered to rapidly cultivate benef...
How the Company Makes Money
null
Hypha Labs Financial Statement Overview
Summary
Hypha Labs exhibits weak financial health with no revenue, persistent losses, negative equity, and negative cash flows. While slight improvement in free cash flow growth offers a minor positive, the overall high financial risk results in a low score.
Income Statement
10Very NegativeBalance Sheet
15Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.70M | 2.50M |
| Gross Profit | -23.96K | 0 | 0 | 0 | 1.07M | 715.16K |
| EBITDA | -1.47M | -2.95M | -1.37M | -58.24K | -1.73M | -249.00K |
| Net Income | -1.91M | -3.10M | -785.00K | 246.77K | -2.06M | -687.00K |
Balance Sheet | ||||||
| Total Assets | 68.33K | 409.22K | 493.81K | 1.41M | 1.34M | 1.89M |
| Cash, Cash Equivalents and Short-Term Investments | 5,110 | 38.12K | 91.17K | 271.01K | 56.17K | 295.93K |
| Total Debt | 1.79M | 1.65M | 1.14M | 2.29M | 2.35M | 2.79M |
| Total Liabilities | 3.16M | 2.51M | 1.42M | 3.28M | 4.08M | 2.94M |
| Stockholders Equity | -3.09M | -2.10M | -926.69K | -1.87M | -2.41M | -1.05M |
Cash Flow | ||||||
| Free Cash Flow | -599.29K | -412.94K | -1.42M | 112.52K | -202.51K | -192.17K |
| Operating Cash Flow | -568.05K | -379.98K | -1.39M | 112.53K | -184.79K | -135.97K |
| Investing Cash Flow | -31.24K | -32.97K | 2.15M | 263.33K | -660.37K | -286.21K |
| Financing Cash Flow | 457.21K | 359.89K | -1.28M | -161.02K | 605.39K | 635.36K |
Hypha Labs Risk Analysis
Hypha Labs disclosed 32 risk factors in its most recent earnings report. Hypha Labs reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksHypha Labs Peers Comparison
Overall Rating
PRPO65Neutral
BIAF43Neutral
FUNI42Neutral
INBS41Neutral
TRIB41Neutral
ISPC40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $34.37M | -31.03 | -7.84% | ― | 21.76% | 22.97% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $3.51M | -0.04 | -331.02% | ― | -18.47% | 87.82% | |
| 42Neutral | $327.79K | -0.16 | 73.84% | ― | ― | 47.23% | |
| 41Neutral | $5.11M | -0.23 | -146.09% | ― | 36.55% | 60.09% | |
| 41Neutral | $3.75M | -0.13 | 48.72% | ― | -13.28% | 39.65% | |
| 40Underperform | $3.09M | -0.02 | -356.00% | ― | -81.99% | 89.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FUNI | Hypha Labs, Inc. | 0.01 | -0.01 | -57.69% | |
| TRIB | Trinity Biotech | 5.83 | -19.21 | -76.73% | |
| PRPO | Precipio | 18.76 | -6.86 | -26.78% | |
| INBS | Intelligent Bio Solutions Inc. | 1.54 | -4.88 | -76.01% | |
| ISPC | Ispecimen Inc | 0.53 | -16.31 | -96.83% | |
| BIAF | bioAffinity Technologies, Inc. | 2.15 | -18.55 | -89.61% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 18, 2026
